Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jean Tayar"'
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Externí odkaz:
https://doaj.org/article/bdd4109fe35746c084a38838cc130920
Autor:
Julianna Martel, MD, Woo Cheal Cho, MD, John S. Runge, PhD, Anisha B. Patel, MD, Jean Tayar, MD, Karin Woodman, MD, Celyne Bueno Hume, MD, Jonathan Curry, MD, Meghan Heberton, MD
Publikováno v:
JAAD Case Reports, Vol 30, Iss , Pp 83-86 (2022)
Externí odkaz:
https://doaj.org/article/2e7441d19ab149f893d5dd045cdf9e83
Autor:
Siqing Fu, Sang T. Kim, Jean Tayar, David S. Hong, Elliot Norry, Amy Sun, Danxia Ke, Juli Miller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
With durable cancer responses, genetically modified cell therapies are being implemented in various cancers. However, these immune effector cell therapies can cause toxicities, including cytokine release syndrome (CRS) and immune effector cell-associ
Externí odkaz:
https://doaj.org/article/91bc53eca31443c2828e9908fd1513a7
Autor:
Omar Mamlouk, Umut Selamet, Shana Machado, Maen Abdelrahim, William F. Glass, Amanda Tchakarov, Lillian Gaber, Amit Lahoti, Biruh Workeneh, Sheldon Chen, Jamie Lin, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Nizar Tannir, Cassian Yee, Adi Diab, Ala Abudayyeh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Rationale & Objective The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of
Externí odkaz:
https://doaj.org/article/9b7f1d1554de4916904fb600cac6c367
Autor:
Dristhi Ragoonanan, Sajad J. Khazal, Rodrigo Mejia, Linette Ewing, Jean-Bernard Durand, Lara Bashoura, Jean Tayar, Natalie Dailey Garnes, Demetrios Petropoulos, Priti Tewari, Micah Bhatti, Ali Haider Ahmad, Jose Cortes, Shehla Razvi, Katrina McBeth, Rita Swinford, Basirat Shoberu, Waseem Waseemuddin, Linda Chi, Jonathan B. Gill, Wafik Zaky, Najat Daw, Cristina Gutierrez, Welela Tereffe, Partow Kebriaei, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Kris M. Mahadeo
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavi
Externí odkaz:
https://doaj.org/article/7cfc638f4d744cde9c9a56cf232f8f52
Autor:
Adi Diab, Faisal Fa’ak, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Stephen Gruschkus, Daniel Johnson, Chantal Saberian, May Daher, Sang Kim, Maryam Buni, Kaysia Ludford
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f6d37aa6536145f49bd865d8184367a7
Autor:
Vickie R. Shannon, Ramona Dadu, Robert Yu, Sanjay Shete, Noha Abdel-Wahab, Jean Tayar, Adi Diab, Maria E. Suarez-Almazor, Andrew Futreal, Lindsey A. Criswell
Publikováno v:
Cancer Immunology, Immunotherapy. 70:1939-1949
Immune checkpoint inhibitors (ICIs) can cause profound immune-related adverse events (irAEs). The host genetic background is likely to play a role in irAE susceptibility because the presentation of toxicity varies among patients and many do not devel
Autor:
Jason D. Robinson, Maher Karam‐Hage, George Kypriotakis, Diane Beneventi, Janice A. Blalock, Yong Cui, Roberto Gonzalez, Jean Tayar, Patrick Chaftari, Paul M. Cinciripini
Publikováno v:
Am J Addict
BACKGROUND AND OBJECTIVES: Bupropion extended release (XL; once-daily dosing) has equal efficacy with the sustained release (SR) formulation (twice-daily dosing) for treating depression, but no studies have compared the two formulations for the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4a045b0e63c441eb13f35142f1f896
https://europepmc.org/articles/PMC9117427/
https://europepmc.org/articles/PMC9117427/
Autor:
Liang Li, Leung Cheuk Hong, Harish Siddhanamatha, Xerxes Pundole, Heather Lin, Natalia V. Zamora, Jean Tayar, Maria E. Suarez-Almazor
Publikováno v:
Clinical Rheumatology. 39:787-794
Biologic disease-modifying anti-rheumatic drugs (bDMARDs) interfere with the immune system and could theoretically increase risk of malignancies. However, recent evidence has not substantiated such concerns and physicians are less reluctant in treati
Autor:
Sang T. Kim, Elliot Norry, Jean Tayar, Amy Sun, Juli Miller, Danxia Ke, Siqing Fu, David S. Hong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
With durable cancer responses, genetically modified cell therapies are being implemented in various cancers. However, these immune effector cell therapies can cause toxicities, including cytokine release syndrome (CRS) and immune effector cell-associ